Tumor markers in patients with pancreatic carcinoma

Cancer

Volumn 78, Issue 1, 1996, Pages 57-62

  Gattani, Anna M ^a   Mandeli, John ^a   Bruckner, Howard W ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CA 125; CA 19 9; CEA; chemotherapy; pancreatic carcinoma; radiotherapy; tumor markers

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; FLUOROURACIL; STREPTOZOCIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DIAGNOSIS; FEMALE; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; PANCREAS ADENOMA; PANCREAS CARCINOMA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; TUMOR BIOPSY;

CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0029951550     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960701)78:1<57::AID-CNCR10>3.0.CO;2-6     Document Type: Article

References (29)

1. Glenn J, Steinberg WM, Kurtzman SH, Sternberg SM, Sindelair W. Evaluation of the utility of a radio immunoassay for serum CA19-9 levels in patients before and after treatments of carcinoma of the pancreas. J Clin Oncol 1988;6(3):P462-8.
2. Beretta E, Malesci A, Zerbi A, Mariam A, Carbucci M, Bonato C, et al. Serum CA19-9 in the post surgical follow up in patients with pancreatic cancer. Cancer 1988;15:2428-31.
3. Ozaki H, Kinoshita T, Kosuge T, Shimade K, Yamamoto J, Egawa S. Evidence of effective multidisciplinary treatment for resectable pancreatic cancer from the viewpoint of the CA19-9 level. Int J Pancreatol 1991;9:159-63.
4. Tempero M, Takasaki H, Metzger HR, Pour P. Tumor antigen levels predict survival in pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 1989;8:113.
5. Gupta MK, Arciaga R, Bocci L, Tubbs R, Bukowski R, Deodhar SD. Measurement of a monoclonal antibody defined antigen (CA 19-9) in the sera of patients with malignant and non malignant diseases. Comparison with carcinoembryonic antigen. Cancer 1985;56:277-83.
6. Steinberg WM, Gelfand R, Anderson KK. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 1983;90:343-9.
7. Basso D, Fabris C, Delfavero G, Angonese C, Meggiato T, Infantino A, et al. Serum carcinoembryonic antigen in the differential diagnosis of pancreatic cancer: influence of tumor spread, liver impairment, and age. Dis Markers 1988;16:203-7.
8. Chevinsky AH. CEA in tumors of other than colorectal origin. Semin Surg Oncol 1991;7:162-6.
9. Ona FV, Zamcheck N, Dhar P, Moore T, Kupchik, HZ. Carcinoembryonic antigen (CEA) in the diagnosis of pancreatic cancer. Cancer 1973;31:324-7.
10. Omar YT, Al-Nayeeb N, Elnos SA, Anwad AH, Foudeh MO, Safadi NB, et al. Serum levels of CA125 in patients with gastric intestinal cancers. Tumour Biol 1989;10:316-23.
11. Lehmann U, Klapdor R, Bahlo M, Greten H. The new tumor associated antigen CA125 in gastrointestinal disorders [abstract]. Digestion 1984;30:121.
12. Bruckner HW, Kalnicki S, Dalton J, Snady H, Schwartz GK, Chesser MR, et al. Survival following combined modality therapy for pancreatic cancer. J Clin Gastroenterol 1993; 16(3):199-203.
13. Bruckner HW, Kalnicki S, Dalton J, Schwartz GK, Chesser MR, Mandeli J, et al. Combined modality therapy increasing local control of pancreatic cancer. Cancer Invest 1993; 11(3):241-6.
14. DelVillano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, et al. Radioimmunometric assay for a monoclonal antibody defined tumor marker CA 19-9. Clin Chem 1983;29:549-52.
15. Bast RC Jr., Klug TL, St. John E, Jenision F, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monodoxol antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7.
16. Klug TL, Bust RC Jr., Niloff JM, Knapp RC, Zurawski VR. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA125) associated with human epithelial ovarian carcinomas. Cancer Res 1984;44:1048-53.
17. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. SAS Institute Inc. SAS User's Guide: statistics (Version 5 edition). Cary, NC: SAS Institute Inc, 1985.
19. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons, 1980.
20. BMDP Statistical Software. BMDP statistical software manual. Berkeley: University of California Press, 1985.
21. The Gastrointestinal Tumor Study Group. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high-dose radiation (4000 rads) + 5-fluorouracil. Cancer 1958;48:1705-10.
22. Weese JL, Nussbaum ML, Paul AR, Engstrom PF, Solin LJ, Kowalyshyn MJ, et al. Increase resectability of locally advance pancreatic and periampullary carcinoma with neo-adjuvant chemoradiotherapy. Int J Pancreatol 1990;7:177-85.
23. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987;59(12):2006-10.
24. Yeung RS, Weese JL, Hoffman JP, Solin LJ, Paul AR, Engstrom X, et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. Cancer 1993;72(7):2124-2133.
25. Wagener DJ TH, de Mulder PH M, Wils JA. Multimodality treatment of locally advanced pancreatic cancer. Ann Oncol 1994;3(5 Suppl):81-6.
26. Wagener D, Rougier P, Wils J, et al. Combined chemoradiotherapy for locally advanced pancreatic cancer. Proc Am Soc Clin Oncol 1993;11:166.
27. Wagener DJT, Van Hoesel QGCM, Yap SH, et al. Phase II trial of 5-fluorouracil, Adriamycin and cisplatin (FAP) followed by radiation and 5-fluorouracil in locally advanced pancreatic cancer. Cancer Chemother Pharmacol 1989;25:131-134.
28. Rich TA, Ajani JA. Stomach, pancreas, biliary system. In: John MJ, Flam MS, Phillips F, Fegha SS, editors.: Chemoradiation: an integrated approach to cancer treatment. Philadelphia: Lea & Febiger, 1995:303-14.
29. Moore M, Anderson J, Burris H, Tarassoff P, Green M, Casper E, et al. A randomized trial of gemcitabine versus 5-FU as first line therapy in advanced pancreatic cancer. Proc Am Soc Clin Oncol 1995;14:102-199.